Elan and Biogen hoping to relaunch MS drug

Elan and Biogen Idec are hoping to relaunch their drug Tysabri to the market as a treatment for multiple sclerosis.

Elan and Biogen hoping to relaunch MS drug

Elan and Biogen Idec are hoping to relaunch their drug Tysabri to the market as a treatment for multiple sclerosis.

They have said they expect to submit additional safety information to US regulators in the next few weeks.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited